Corcept execs enjoy raises in wake of drug OK

The San Francisco Business Times reports that Corcept Therapeutics execs earned 10% salary hikes after last year's approval of the Cushing's syndrome drug Korlym. CEO Joe Belanoff led the pack with an expanded $530,000 salary, up from $481,097. The rare-disease therapy costs up to $20,000 a month. Story

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.